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ABSTRACT Neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic 
lateral sclerosis (ALS), Huntington’s disease (HD), and spinocerebellar ataxias (SCA) are very important both for 
fundamental science and for practical medicine. Despite extensive research into the causes of these diseases, clinical 
researchers have had very limited progress and, as of now, there is still no cure for any of these diseases. One of the 
main obstacles in the way of creating treatments for these disorders is the fact that their etiology and pathophysiology 
still remain unclear. This paper reviews results that support the so-called “calcium hypothesis of neurodegenerative 
diseases.” The calcium hypothesis states that the atrophic and degenerative processes in the neurons of AD, PD, ALS, 
HD, and SCA patients are accompanied by alterations in calcium homeostasis. Moreover, the calcium hypothesis states 
that this deregulation of calcium signaling is one of the early-stage and key processes in the pathogenesis of these 
diseases. Based on the results we reviewed, we conclude that the calcium channels and other proteins involved in the 
neuronal calcium signaling system are potential drug targets for AD, PD, ALS, HD, and SCA therapy.
KEYWORDS Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis, Huntington’s disease, spi-
nocerbellar ataxias, calcium channels, calcium signaling, mitochondria, transgenic mice, clinical trials, imaging, me-
mantine, dimebon, riluzole.  
ABBREVIATIONS  ER – endoplasmic reticulum, MCU – mitochondrial Ca2+ uniporter, AD – Alzheimer’s disease, PD – 
Parkinson’s disease, ALS – amyotrophic lateral sclerosis, HD – Huntington’s disease, SCA – spinocerbellar ataxias, Htt 
– huntingtin protein, NMDAR – N-methyl-D-aspartate receptors, MSN – medium spiny neurons, TBZ – tetrabenazine, 
HAD – heritable Alzheimer’s disease, PtdS – phosphatidyl serine. InsP3R1 – type 1 inositol (1,4,5)-trisphosphate recep-
tor, mPTP mitochondrial permeability transition pore
C
alcium signaling in neurons connects membrane excit-
ability with the biological function of the cell [1]. Since 
Са2+ channels are located on the boundary between 
the “electrical” and the “signaling” worlds, they play a key 
role in various aspects of the neuronal function. Ca2+ signaling 
is required for short-term and long-term synaptic plastic-
ity. Because of its extreme importance, neurons use multiple 
mechanisms to control intracellular levels of Ca2+, usually 
within local signaling microdomains.
NEURONAL Ca2+ SIGNALING
A variety of Ca2+ channels are involved in neuronal Ca2+ sig-
naling: the voltage-dependant Ca2+ channels of the plasma 
membrane (VGCC ), NMDA receptors, AMPA receptors, 
TRP channels, and depot-controlled channels. Release of 
Ca2+ from the intracellular ER depot is mediated by inositol-
1,4,5-triphosphate receptors (InsP3R) and ryanodine recep-
tors (RyanR). The SERCA pump in the ER, the Ca2+ pump 
of the plasma membrane, and the  Na+/Ca2+ exchanger of 
the plasma membrane are involved in the accurate control 
of the Ca2+ level in the cytosol in a very narrow range. The 
mitochondria play a very important role in the formation 
of cytosolic Са2+ signals. The mitochondrial Ca2+ uniporter 
(MCU) is an ion channel involved in the rapid and massive 
entrance of calcium into the mitochondria. A large number of 
Ca2+-binding proteins are involved in maintaining a certain 
level of Ca2+ in the cytosol (such as calbindin-D28, calretinin, 
and parvalbumin) and inside the ER (such as calreticulin and 
calnexin) in neurons. 
Since neurons are highly sensitive to changes in the intra-
cellular Ca2+ concentration, they have a whole range of Ca2+-
dependent structures, including proteins that are involved 
in the fusion of synaptic vesicles with the presynaptic mem-
brane (such as synaptotagmins), Ca2+-dependant kinases and 
phosphatases (such as the Ca2+/CaM kinase and the Ca2+-de-
pendant phosphatase calcineurin), Ca2+-dependent signaling 
enzymes (such as Ca2+-dependent adenylate cyclase and Ca2+-
dependent NO-synthase), and Ca2+-dependent transcription 
factors (such as the cAMP-dependent element-binding pro-
tein, calcineurin B-controlled activated T-lymphocyte nucle-REVIEWS
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ar factor, and Ca2+ binding downstream regulatory element 
modulator). Such a variety of Ca2+-dependent elements makes 
the fine Ca2+-dependent regulation of a neural function on 
time-scales possible in the microsecond range (as is the case 
of the Сa2+-dependent fusion of a synaptic vesicle with the 
presynaptic membrane), in second and minute ranges (as in 
the case of Ca2+-dependent phosphorylation and dephospho-
rylation), and up to day and year ranges (for Ca2+-dependent 
changes in neural gene expression). These Ca2+-dependent 
processes lead to short- and long-term changes in neuronal 
excitability (by changing the activity of ion channels and the 
expression pattern) and changes in synaptic transduction (by 
modifying the synaptic machinery and forming or disjoining 
synaptic connections). Since neurons are extremely sensitive 
to changes in Ca2+ signaling, even fine defects and deregula-
tion of Ca2+ signaling can have destructive consequences [2]. 
CA2+  BLOCKERS AND A COMPLEX APPROACH FOR 
TREATING NEURODEGENERATIVE DISORDERS 
Neurodenerative disorders, such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), 
Huntington’s disease (HD), and spinocerbellar ataxias (SCA), 
are a very important problem both for fundamental science 
and for practical medicine. Despite extensive research into 
the causes of these diseases, clinical researchers have had 
very limited progress and as of now there is still no cure for 
any of these diseases. Therapeutic drugs used for treating 
these disorders have only a limited effect, causing only tem-
porary relief of the symptoms or slowing the disease’s pro-
gression (Table 1). A significant advance in the study of these 
disorders was achieved with the discovery of mutations that 
cause the pathological processes. HD and SCA are genetic dis-
orders, and the genes which cause these diseases were cloned 
around 15 years ago (Table 1). Most cases of HD, PD, and ALS 
are sporadic, but around 5% of the patients inherit the disor-
der. Most of the genes which are involved in the development 
of the heritable form of the disease have been cloned (Table 
1). The study of the genes which cause the above-mentioned 
diseases allowed researchers to form a mechanistic hypoth-
esis for the pathological process and creates a mouse model 
for studying these pathologies. Most attempts at studying the 
above-mentioned pathologies are focused on identifying the 
main causes of diseases and developing approaches to affect 
these causes. For instance, the main cause of AD was thought 
to be the formation of amyloid. Because of this, the main re-
search efforts are directed at preventing the accumulation 
of amyloid by blocking its production or facilitating its clear-
ance from the brain. In case of HD, the main reason is the 
expression of a mutant form of the huntingtin (Htt) protein. 
This means that most experimental efforts are directed at 
lowering mutant Htt expression in the brain (such as by using 
interfering RNA or a antisense knockdown).
Despite impressive scientific results, these approaches are 
hard to use in clinical treatment. For instance, in case of AD, 
the clinical trials of the amyloid-binding drug trampiprosate 
(Alzhemed) and the γ-secretase inhibitor tarenflurbil (Fluri-
zan) were both unsuccessful. Clinical trials of amyloid-binding 
monoclonal antibodies (Bapineuzumab) had a very limited or 
even a negligible effect. The clinical trials of approaches for 
treating HD have problems with devising an adequate ap-
proach for siRNA or antisense RNA delivery into the human 
brain. There is still no solution for this problem, and clinical 
trials cannot be performed. While the focused attention on 
amyloid and mutant Htt is understandable, it is worth men-
Table 1. Neurodegenerative diseases (Bezprozvanny, 2009)
Disease  Affected neurons Age of 
onset
Sporadic/
inherited Genes Drugs Target       Effect
AD
Neurons of the 
cortex and hip-
pocampus
>65 95% sporadic, 
5% inherited
APP
PSEN1
PSEN2
Namenda 
(Memantine) 
Blocks NMDA-receptors, 
reduces toxicity
Moderately 
improves cognitive 
function
Donepezil (Aricept), 
Galantamine 
(Razadyne), 
Rivastigmine 
(Exelon)
Inhibitors of acetylcholine 
esterase. Increase the amount 
of acetylcholine in the brain
Moderately 
improves cognitive 
function
PD 
Dopaminergic 
neurons of the pars 
compacta of the 
substantia nigra
>65 95% sporadic, 
5% inherited
Synucl 
LRRK2
Parkin  
PINK1 
DJ-1
L-Dopa (Levodopa)
Increases the amount of 
dopamine in the neurons of 
the substantia nigra
Symptomatic 
relief 
ALS  Motor neurons 40–60 95% sporadic, 
5% inherited SOD1 Riluzole (Rilutek) 
Antiglutamate effect (acti-
vates the capture of gluta-
mate, blocks the NMDAR 
receptor and Na-channels)
Increases life-span 
by a few months
HD 
Medium spiny  
neurons of the 
striatum
40–50 100% 
inherited Huntingtin Tetrabenzine 
(Xenazine)
Antidopamine effect (inhibits 
VMAT, lowers the amount of 
excreted dopamine)
Reduces chorea
SCA
Various regions of 
the brain involved 
in motor control
40–50 100% 
inherited Ataxins None None None 74 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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tioning that the collected data indicate that these are tar-
gets which are very difficult to affect and that the creation 
of successful therapy based on these approaches will take a 
long time and take up considerable resources. In addition to 
developing methods for treatment, we propose a treatment 
that can delay the age at which the symptoms of the disease 
are manifested and/or lower the degree of the disease mani-
festation. Further, we will focus attention on the concept that 
the proteins involved in the calcium signaling in neurons are 
promising targets for developing “disease-delaying” therapy 
for neurodegenerative pathologies. We surmise that the most 
promising approach for clinical treatment will be a combi-
nation of approaches developed for each disease (such as 
amyloid-directed therapy for AD and huntingtin-directed 
therapy for HD) and of Ca2+ blockers.
NEURONAL Ca2+ SIGNALING AND AGING
Our neurons are the same age as us. Thus, it is not surpris-
ing that the risk of neurodegenerative diseases increases 
with age (Table 1). Comparative studies of neurons from 
young and old rodents have shown that the neuronal Са2+-
signaling system experiences changes during aging. These 
data have been extensively published in the scientific press 
[2]. Recently, an integral model of age-dependent changes 
in hypocampal Ca2+ signaling has been proposed [3]. One of 
the main features of aging neurons is an increase in the Ca2+ 
concentration via active Ca2+ release from the intracellular 
depot using InsP3R and RyanR, an increased release of Ca2+ 
through the L-type VGCC, an increase of the slow trace hy-
perpolarization caused by the activation of Ca2+-dependent 
K+ channels, a lowered involvement of NMDAR-mediated 
Ca2+ entrance, and a lowered buffer capacity of the cytosol 
and activation of calcineurin and calpains. Such changes in 
the neuronal Ca2+ dynamics lead to increased sensitivity, to 
the induction of long-term depression, and to the increased 
threshold frequency required for long-term potentiation in 
aging neurons [4]. The importance of these changes was also 
discussed in connection with the age-dependent disorders of 
the memory function [4].
The mechanisms involved in age-dependent changes in 
neuronal Ca2+ signaling have still not been elucidated. One 
possible scenario is connected with the age-dependent defects 
of mitochondrial function caused by the overall oxidative 
damage sustained by the mitochondria. The mitochondria of 
aged neurons are depolarized and less effective in the control 
of Ca2+ uptake [2]. Age-dependent changes in the transcrip-
tion of Ca2+-signaling proteins were also discovered [2]. Some 
of these changes were directly dependent on the aging pro-
cess and some of them were compensatory, but the whole 
picture is in agreement with the presence of age-dependent 
changes in the neuronal Са2+-signaling system on various lev-
els. 
NEURONAL CA2+ SIGNALING AND HUNTINGTON’S DISEASE
Huntigton’s disease (HD) is a genetic disorder which is 
caused by a single mutation: the expansion of the CAG (poly-
glutamine) repeat in the huntingtin (Htt) gene [5] (Table 1). 
Medium spiny neurons (MSN) in the striatum are cells that 
sustain the most damage during HD. Most researchers agree 
that the mutant protein Httexp experiences a “gain of its toxic 
function” [6]. The destabilization of neuronal Ca2+ signaling 
is one of the toxic functions of the Httexp protein. Studies of 
HD patient’s brains and also model experiments with mice 
show that the brain experiences sequential changes in the 
expression levels of Ca2+-signaling proteins [7]. We proposed 
the “calcium hypothesis for HD” [8]. There are several main 
pathways for the effect of Httexp on Ca2+ signaling in MSN 
(Fig. 1). Our laboratory has established that Httexp directly and 
specifically binds the C-terminus of InsP3R1 [9]. The associa-
tion between Httexp and InsP3R1 was independently discov-
ered by random screening [10]. Binding with Httexp increases 
the affinity of InsP3R1 for InsP3 [9]. The key role of InsP3R1 
activation in Httexp neurotoxicity was confirmed experimen-
tally in mouse MSN cultures, which were used to model HD 
[11, 12], and in genetic experiments on the Drosophila based 
Fig. 1. A model of Ca2+ deregulation during HD (cited from (Tang et al.,
2007)). In MSNs during HD, Httexp disrupts Ca2+ signaling by three 
synergistic mechanisms. Httexp increases the function of the NR2B-
bearing NMDA receptor (probably by increasing its transport into the 
plasma membrane). Httexp tightly binds to the С-terminus of InsP3R1 and 
increases its affinity to InsP3.
The low level of glutamate secreted by the neurons of the corticostriatal 
projection causes an excessive influx of Ca2+ via the NMDA receptor 
and the release of Ca2+ from the ER via InsP3R1. The additional uptake 
of Ca2+ into MSNs is mediated by VGCC. Dopamine excreted by the 
dopaminergic neurons of the mesencephalon stimulates the type-1 (D1R) 
and type-2 (D2R) dopamine receptors, which are highly expressed in 
MSN. D1R is connected with an adenylate cyclase, and together they 
increase the cAMP level and activate the protein kinase A (PKA). PKA 
enhances the glutamate-induced Ca2+ signals by increasing the activity of 
the NMDA receptor and InsP3R1. D2R is directly involved in the produc-
tion of InsP3 and the activation of InsP3R1. The excessive uptake of Ca2+ 
activates calpain, which cleaves Httexp and other substrates. The excess 
of Ca2+ in the cytosol leads to the capture of Ca2+ by the mitochondria 
via MCU, which in turn induces the opening of mPTP and apoptosis. The 
calcium regulation of mitochondria is also disrupted due to the direct 
interaction between Httexp and the mitochondria. The antidopamine 
drug tetrabenzine (TBZ) has been approved in the United States for the 
symptomatic treatment of HD. The NMDA receptor antagonist memantin 
(MMT), the soluble “mitochondrial agent” dimebon and “mitochondrial 
stabilizers” creatin and coenzyme Q10 (CoQ10) are all in clinical trials. 
The antiglutamate agent Riluzole has passed clinical trials, but it turned 
out to be ineffective for HD treatment [19]REVIEWS
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HD model [10]. Recent studies show that the viral delivery 
of a peptide that destabilizes the interaction between Httexp 
and InsP3R1 has a protective effect on the striatum MSN in 
the mouse HD model both in in vitro and in vivo conditions 
[13]. These data confirm the importance of increased InsP3R1 
activity in HD pathogenesis. The expression of Httexp causes 
increased activity of the NR 2B-bearing NMDA-receptor [14]. 
The increased flow through the NMDA-receptor is a conse-
quence of the effect of Httexp on the transport of the NMDA-
receptor to the plasma membrane [15]. Striatum MSNs ex-
pressing Httexp are sensitive to NMDAR-mediated toxicity. 
The pharmacological inhibition of the NMDA-receptor has 
a neuroprotective effect on a mouse MSN HD-model culture 
[11, 16]. Both memantin and riluzole had a neuroprotective 
effect on MSN cultures with HD. Memantin was more effec-
tive [17]. Memantin also had some positive effects in a small-
scale experimental survey of this drug on HD patients [18], 
and it will soon be in the fourth phase of clinical trials for HD 
therapy (Table 2). Riluzole has completed the third stage of 
clinical trials on HD patients, but this study did not turn out 
to be successful [19] (Table 2). 
In addition to InsP3R1 and to the NMDA-receptor, Httexp 
can also affect potential-dependent Ca2+ channels (VGCC). 
Huntingtin directly binds the α2/δ accessory subunit of 
VGCC [10] and the CaV2.2 pore-forming subunit of N-type 
VGCC [20]. The genetic removal of Dmca1D (pore-forming 
subunit of the L-type calcium channel in Drosophila) decreas-
es the neurodegeneration of the photoreceptor in HD-model 
fruit flies [21]. An electrophysiological analysis of the striatum 
neurons of HD-model mice showed an initial increase of the 
VGCC channel density, which was followed by a decrease in 
their density [22]. Just as for other neurodegenerative dis-
orders, Ca2+ toxicity mechanisms during HD are most often 
mediated by calpain activation and Ca2+ accumulation in the 
mitochondria (Fig. 1). The activation of calpains is observed 
during HD, and calapin-mediated cleavage of Httexp and the 
NMDA-receptor plays a key role in the pathology of this dis-
ease [23–25]. A large body of evidence indicates mitochondri-
al dysfunction during HD [26]. Mitochondria isolated from the 
HD patient’s lymphoblasts and from the brains of transgenic 
HD mice exhibited clear defects of the calcium system regu-
lation [27]. The mitochondrial function was also disrupted in 
cell HD models [11, 12, 16, 28]. In addition to the effect on the 
mitochondria caused by the excessive concentration of Ca2+ in 
the cytosol, Httexp can also affect these organelles by directly 
binding with their outer membrane [27] (Fig. 1). It is worth 
noting that clinically adequate inhibitors of mitochondrial 
membrane permeability demonstrated a neuroprotective ef-
fect both on cellular HD models and on animal models of this 
disease [11, 28].
The first drug approved for HD treatment in the United 
States in 2008 was a dopamine tetrabenzine antagonist (TBZ) 
(Table 1). TBZ is a powerful inhibitor of the monoamine vesic-
ular transporter, which causes the depletion of the dopamine 
contents of presynaptic vesicles. The clinical trials demon-
strated that TBZ had a reliable suppressor effect on chorea 
symptoms in HD patients [29]. Our laboratory studied the ef-
fects of TBZ on the mouse HD model. It was shown that the 
Table 2. The most recent clinical trials of Ca2+ inhibitors and mitochondrial stabilizers as treatments for neurodegenerative disorders
Disorder Drug Target Clinical trial 
stage Clinical trial ID Information was 
supplied by Status/commentary
AD
Dimebon mitochondrion (?) Phase III NCT00675623 Medivation
Completed, unsuccessful
http:// www.alzforum.org/new/detail.
asp?id=2387
Ketasyn 
(AC-1202) mitochondrion Phase II NCT00142805 NIA Completed
MEM-1003 L-type VGCC Phase II
NCT00257673
NCT00257673
NCT00257673
Memory 
Pharmaceuticals Completed
EVT-101 NR 2B NMDA-
receptor Phase I NCT00526968 Evotec 
Neurosciences Completed, Phase II is planned
HD
Dimebon mitochondrion (?) Phase II NCT00497159 Medivation Completed, weak effect on cognitive function
Creatine mitochondrion Phase III NCT00712426 MGH Forming test subject group
Coenzyme 
Q10 (CoQ10) mitochondrion Phase III NCT00608881 NINDS Forming test subject group
Memantine NMDA-receptor Phase IV NCT00652457 UCSD Forming test subject group
Riluzole antiglutamate Phase III NCT00277602 Sanofi-Aventis Completed, unsuccessful ([19], 2007)76 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
REVIEWS
effect of this drug lowered the deficit of motor coordination 
in the early stages of the disease and protected the striatum 
neurons from degeneration under in vivo conditions [30]. It 
was concluded that dopamine and glutamate have a syner-
getic activity in the formation of Ca2+ signals in the neurons 
of the striatum and that the effect of TBZ might be due to 
lowered Ca2+ signaling [30] (Fig. 1). These facts confirm that 
TBZ cannot only be used as a drug for symptomatic treat-
ment on late stages of the disease, but also as a drug for treat-
ing the disease presymptomatically. However, TBZ caused 
strong depression in some patients [29], which is why alterna-
tive dopamine antagonists should be researched, for instance, 
the dopamine-specific inhibitor of the vesicular monoamine 
transporter or blockers of D1 or D2 receptors. 
NEURONAL CA2+ SIGNALING AND SPINOCERBELLAR ATAXIAS
Like in the case of HD, spinocerbellar ataxias (SCA) are auto-
somal dominant genetic disorders caused by the expansion of 
the polyglutamine sequence in ataxin proteins (Atx) [5]. There 
is a number of observations which indicate that disorders in 
the neuronal Ca2+ signaling can play a role in the pathogenesis 
of these diseases. Some of these data are presented further. 
SCA1 leads to the degeneration of Purkinje cells of the 
cerebellum caused by the expansion of CAG repeats in the 
cytosol/nuclear protein ataxin-1 [5]. Purkinje cells of the cer-
ebellum express very high levels of Ca2+-signaling proteins 
and Ca2+-binding proteins. A decrease in the Ca2+-binding 
proteins in Purkinje cells was also observed in patients with 
early-stage SCA1 and in mouse models of this disease [31]. 
Crossing transgenic SCA1 mice with calbindin knockout mice 
led to an increased disease phenotype [31]. The transgenic 
CMA1 mouse model made it possible to observe the low-
ered expression of Ca2+-signaling proteins such as InsP3R1, 
Ca2+-channel TR PС3, and the ER pump SERCA2 during the 
early stages of the disease [32]. Albeit indirectly, these data 
confirm the fact that the disruption of the calcium signaling 
in Purkinje cells probably plays a key role in the etiology of 
SCA1. 
During SCA2, the Purkinje cells of the cerebellum experi-
ence degeneration due to the expansion of CAG repeats in the 
cytosolic protein ataxin-2 [5]. The genetic connection between 
the polymorphism of the type-P/Q VGCC sequence and the 
age at which the first symptoms of SCA2 are manifested 
confirms the fact that Ca2+ signaling plays a very important 
role in the pathogenesis of this disease [33]. Our laboratory 
has discovered that the mutant form of ataxin-2 specifically 
binds and activates InsP3R1 similarly to the mutant form of 
Htt (article in print). We also demonstrated that inhibitors of 
Ca2+ signaling protected Purkinje cells from apoptosis during 
SCA2 under in vitro conditions and had a pronounced positive 
effect in experiments on transgenic mice (article in print).
During SCA3, neurons of the substantia nigra and the pon-
tine nuclei experience degeneration as a result of the CAG 
repeat expansion in the ataxin-3 cytosolic protein [5]. Calpain-
mediated cleavage of ataxin-3 plays an important role in the 
pathogenesis of SCA3 [34]. Recently, we showed that the mu-
tant form of ataxin-3 specifically binds and activates InsP3R1 
similarly to how it binds the mutant form of the Htt protein 
[35]. It was further determined that the long-term feeding 
of CMA3 mice with a RyanR inhibitor and the Ca2+ stabilizer 
dantrolen facilitated the age-dependent deficit of motor coor-
dination in these mice and prevents the loss of neurons in the 
substantia nigra and the pontine nuclei [35].
SCA6 causes Purkinje cells of the cerebellum to degenerate 
as a result of the expansion of CAG repeats in the C-terminus 
of the CaV2.1 (the pore-forming subunit of the P/Q-type Ca2+ 
channel) [5]. It was reported that this mutation increased the 
activity of the P/Q-type Ca2+ channel in an expression system 
[36]. However, most recent studies of SCA6 mice have shown 
that this pathology is also associated with the aggregation 
of CaV2.1 subunits and with the reduced density of the Ca2+ 
flow through the P/Q-type channels in dendrites [37]. Thus, 
the issue of the precise role of Ca2+-signaling deregulation 
during SCA6 still remains unresolved. Anomalous neuronal 
Ca2+ signaling is not limited to ataxias with expanded poly-
glutamine repeats, but it can also play an important role in 
the ataxias of other types. The most recent genetic studies 
have shown that the cause of SCA15 is the loss of a fragment 
of the InsP3R1 gene [38].
NEURONAL CA2+ SIGNALING AND ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is a neurodegenerative disorder 
which causes memory loss. In most cases, AD appears sporadi-
cally and the first symptoms emerge in the elderly (after 60). A 
small fraction of cases (heritable AD (HAD)) are characterized 
by the early onset of symptoms and genetic inheritance.
NEURONAL CA2+ SIGNALING AND SPORADIC AD
Sporadic AD is a “multitraget” disorder caused by the syn-
ergistic effect of several pathological factors. One of these 
factors is aging. The other factors are determined by the 
populations of neurons affected by the disease, in this case 
the cortical and hypocampal neurons. The main “disease-
specific” factor during AD is probably the accumulation 
of amyloid. Since AD is a multitarget disease, the success-
ful therapy must have a complex nature. The population of 
neurons which express high levels of Ca2+-binding proteins 
remain mostly untouched by AD, while the populations of 
neurons which express these proteins at a low level experi-
ence extensive damage. A decreased level of Ca2+-binding 
proteins is one of the most usual consequences of the natural 
aging process. Most likely one of the causes of an increased 
susceptibility of aged neurons to AD is the decreased buffer 
capacity of the neuronal cytosol for Ca2+. Neurons of elderly 
patients who suffer from the sporadic form of AD exhibit an 
activation of Ca2+-dependent proteases of the calpain family. 
Calpain activation takes place as a response to the increased 
levels of Ca2+ in the cytosol. Activated calpains cleave various 
proteins which are required for the normal functioning of the 
neuron, which results in neuronal dysfunction and apoptosis.
The mitochondria in neurons of AD patients experience 
severe damage. These organelles are partly depolarized, they 
exhibit lowered ability to bind Ca2+, the disruption of the stoi-
chiometry of the electron transfer chain, and the mutation of 
the mitochondrial DNA. Similar – but less visible – changes 
also take place in the mitochondria during the natural aging 
process. Damage to the mitochondria is probably caused by 
an oversaturation of this organelle by Ca2+, which causes the 
formation of large quantities of active forms of oxygen, which 
then cause extensive oxidative damage to the mitochondrial REVIEWS
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DNA. Thus, mitochondria seem to be the final step in the cal-
cium-signaling chain of this pathogenic cascade. However, 
it is still expected that “mitochondrial stabilizers” (such as 
coenzyme Q10 and creatine) should have some positive ef-
fect on these disorders. Drugs which are targeted at the mi-
tochondrial permeability transition pore (mPTP) should be 
extremely useful as a “last line of defence” for the neuron 
delaying of the onset of neuronal dysfunction and cell death. 
The aging process affects neuronal Ca2+ signaling and 
seems to be one of the factors involved in pathogenesis during 
sporadic AD. Thus, it is expected that blockers of Ca2+ sign-
aling can have a positive effect on this disease. The NMDA-
receptor antagonist Memantin has demonstrated a certain 
degree of clinical efficiency in AD treatment. The treatment 
of this disease requires the development and clinical trial of 
new Ca2+-signaling blockers by themselves and as part of a 
complex therapy in combination with mitochondrial stabiliz-
ers and with mPTP inhibitors.
NEURONAL SIGNALING AND HAD
The calcium hypothesis of AD pathogenesis. The central idea 
for explaining AD pathology is currently the amyloid hy-
pothesis, which states that the main reason for neuron death 
and the decreased number of synapses during this disorder 
is the increased production of Aβ42 amyloid peptide (or the 
increased Aβ42/40 ratio) [39].
Experimental proof of the amyloid hypothesis is based on 
the following facts: (1) amyloid plaques are accumulated in 
the brains of AD patients; (2) the heritable form of AD (HAD) 
is caused by nonsense-mutations in the β-amyloid Aβ precur-
sor protein (АРР); and (3) HAD is also caused by nonsense 
mutations in presenilins, which form the catalytic subunit 
of γ-secretase, an enzyme that cleaves APP. Currently, am-
yloid-directed therapy is the central strategy in developing 
drugs for AD therapy. Recent clinical trials have shown that 
targets other than amyloid need to be found in order to cre-
ate an effective therapeutic solution for the treatment of AD 
[40]. A large mass of data indicates that the disruption of Са2+ 
homeostasis in neurons plays a significant role in AD patho-
genesis. The data in favor of the calcium hypothesis of AD de-
velopment have been actively discussed in recent years [41]. 
This hypothesis is reviewed below. One of the key connections 
between AD pathogenesis and Ca2+ is based on data which 
state that Aβ oligomers can form Ca2+-permeable channels 
in membranes [42]. The ability of Aβ oligomers to associate 
with membranes is enhanced if the membrane is treated by 
phosphatidylserine (PtdS) [43], which occurs naturally in cells 
experiencing a deficit of energy. Age-related changes in the 
mitochondria can increase the amount of surface PtdS in neu-
rons and thus facilitate the Aβ-mediated formation of pores, 
the uptake of Ca2+, and cell death (Fig. 2). In fact, neurons 
with decreased levels of cytosol ATP and increased levels of 
PtdS are especially sensitive to Aβ-mediated toxicity [44]. 
The ability of Aβ-oligomers to form Ca2+-permeable chan-
nels in the neuron plasma membrane is in agreement with the 
results of the most recent experiments on in vivo measure-
ments of intracellular Ca2+ concentrations on transgenic APP 
mice [45]. The authors of this study demonstrated that the 
quiescent-state Ca2+ levels in approximately 35% of neuronal 
axons located in close proximity to amyloid plaques were reli-
ably higher than in control cells. The most likely explanation 
for this fact is that the local concentration of Aβ-oligomers 
in the regions adjacent to the plaque causes the formation 
of Ca2+-permeable ion channels in the plasma membrane of 
neurons. Axons with increased Ca2+ levels lose their spikes 
and exhibit defective morphology [45]. The morphological 
changes in these axons can be alleviated by the activity of the 
calcineurin inhibitor FK-506 [45]. Based on this fact, we can 
Fig. 2. Model of Ca2+ deregulation in AD (Bezprozvanny and Mattson, 
2008). Sequential cleavage of the β-amyloid precursor-protein (β) by 
the γ-secretase (γ) leads to the formation of Aβ. Aβ forms oligomers, 
which can integrate into the plasma membrane (PM) and form pores 
permeable to Ca2+-ions. The association of Aβ oligomers with the plasma 
membrane is facilitated by binding with the surface phosphatidylserine 
(PtdS); the aging process and Ca2+-mediated damage of mitochondria 
cause a decrease in the ATP level and lead to the transfer of PtdS from 
the inner to the outer surface of the plasma membrane. The decrease of 
the ATP level and the loss of membrane integrity cause membrane depo-
larization, which in turn causes an increase in the uptake of Ca2+ through 
NMDA receptors and VGCC. Aβ oligomers can also directly influence 
the affinity of the NMDA, AMPA, and VGCC receptors. Glutamate acti-
vates mGluR1/5 receptors, increases the production of InsP3, and facili-
tates InsP3-mediated release of Ca2+ from the ER. Presenilins (PS) function 
as channels for Ca2+ drain from the ER and various mutations associated 
with HAD disrupt the Ca2+ drain function of presenilins. This causes the 
excessive accumulation of Ca2+ in the ER. An increase in Ca2+ levels in the 
ER enhances the release of Ca2+ via the type-I InsP3 (InsP3R1) and type-2 
ryanodine receptor (RyanR2). PS can also directly modulate the activity 
of InsP3R, RyanR, and the SERCA pump. The increase in cytosolic Ca2+ 
concentration activates calcineurin and calpains, which in turn enhances 
long-term depression (LTD), suppresses long-term potentiation (LTP), 
and causes the modification of the neuronal cytoskeleton and the loss 
of synapses and axon atrophy. The excessive amount of Ca2+ in the 
mitochondria, which appears due to the activity of mitochondrial calcium 
uniporter (MCU), leads to the opening of the mitochondrial permeable 
transit pore (mPTP) and apoptosis. An inhibitor of the NMDA receptor 
called memantine (MMT) has been approved for AD treatment, and a 
NR2B-specific antagonist EVT-101 has also been developed. Currently, 
several other drugs are under clinical trials for the treatment of AD: a 
“CNS optimized” L-type VGCC inhibitor MEM-1003, the soluble “mito-
chondrial agent” Dimebon, and “mitochondrial antidepressant ” Ketasyn78 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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hypothesize that calcineurin plays an important role in the 
pathological response of neurons to an increase in the level 
of Ca2+. Together with the direct effects on the permeability 
of the plasma membrane for Ca2+ ions, Aβ oligomers also af-
fect the neuronal Ca2+ homeostasis via the modulation of the 
NMDA-receptor [46, 47] (Fig. 2), AMPA-receptor [48], and 
P/Q-type VGCC activity [49].
Another important relationship between Ca2+ signaling 
and AD was discovered from the fact that various muta-
tions of presenilins found in HAD cases cause the deregula-
tion of Ca2+ signaling. Initially, the connection between pre-
senilins and Ca2+ signaling was discovered in a report that 
observed that fibroblasts from patients with HAD released 
abnormally high amounts of Ca2+ in response to the effect 
of InsP3 [50]. Similar data have been obtained in experi-
ments on cells expressing mutant presenilins characterstic 
of AD [51], as well as on murine cortical neurons expressing 
mutant forms of presenilins characterstic of HAD [52, 53]. 
In order to explain these results, researchers hypothesized 
that mutant forms of presenilins affected the depot-con-
trolled uptake of Ca2+ [54, 55], increase the activity and/or 
expression of intracellular Ca2+ ion-channels such as RyanR 
[53, 56, 57] and InsP3R [58, 59], or modulate the function 
of the Ca2+pump SERCA in the ER [60]. Research done in 
our laboratory demonstrates that presenilins by themselves 
can work as channels for the draining of Ca2+ from the ER 
and that numerous mutations of presenilins associated with 
HAD lead to the overstocking of the ER with Ca2+ and the 
excessive release of Ca2+ from the ER [61, 62]. Despite some 
differences in the details of the proposed mechanisms, most 
of the reviewed studies are in agreement with the idea that 
various mutations of presenilins associated with HAD lead 
to the excessive release of Ca2+ from the ER via InsP3R 
and RyanR. There are several effects from releasing Ca2+ 
through the Aβ channels and excessively releasing Ca2+ 
from the ER, which are especially toxic. As was said earlier, 
an increased level of cytosolic Ca2+ can activate calcineurin 
and cause atrophy [45] (Fig. 2). An excessively high level 
of Ca2+ also activates calpains, which destroy signaling en-
zymes involved in the processes of learning and memory 
[25, 63] (Fig. 2). Aged neurons become sensitive to the tox-
icity of cytosolic Ca2+ since aged cells have lower cytosolic 
buffering capacity. 
In fact, an evident correlation has been found between the 
lowered expression of Са-binding proteins in the region of 
the dentate gyrus of the hippocampus and the emergence of 
cognitive disorders associated with AD [64]. Abnormally high 
cytosolic Ca2+ signals can cause the excessive uptake of Ca2+ 
into the mitochondria and lead to cell apoptosis (Fig. 2). The 
known positive effects of nonsteroid anti-inflammatory drugs 
can be explained by their ability to lower the mitochondrial 
uptake of Ca2+ [65].
In conclusion, we must note that a large mass of experi-
mental data demonstrate excessive levels of Ca2+ in the neu-
ronal cytosol as an effect of the Aβ oligomer accumulation 
or of the expression of mutant presenilins characteristic of 
HAD. Further proof of the connection between Ca2+ signal-
ing and AD was obtained from a recent study which dem-
onstrated that a mutation in the new Ca2+-uptake channel 
CALHM1 can increase the risk of late-onset AD [66] (how-
ever, see also [67]). The proposed model (Fig. 2) offers a 
whole range of potential drug targets for AD therapy. The 
Aβ-based Ca2+ channels by themselves are very promising 
drug targets [68]. Thus, the US Food and Drug Administra-
tion has already approved memantin, which is a noncom-
petitive inhibitor of the NMDA-receptor as a therapeutic 
drug for AD (Table 1). There is the possibility of developing 
even more specific inhibitors for the NMDA-receptor, such 
as nitromemantins [69]. Recently, Evotec Inc has developed 
potential AD drugs based on a specific antagonism of NR2B 
receptors : EVT101 and EVT103 (Table 2). An L-type VGCC 
inhibitor MEM-1003 (Memory Pharmaceuticals) has suc-
cessfully passed second stage clinical trials (Table 2). Other 
potential and mostly unstudied targets for AD therapy in-
clude intracellular Ca2+ channels (RyanR and InsP3R), the 
SERCA pump, calcineurin, and the mitochondrial Ca2+ regu-
lation system.
The presented data constitute a new view on the therapy 
of neurodegenerative pathologies. Our proposed Ca2+ hy-
pothesis creates a basis for the development of a new class 
of drugs. 
CA2+ SIGNALING: CURRENT PERSPECTIVES 
FOR THERAPEUTIC APPLICATIONS
Mitochondrial stabilizers and antidepressants. Ketasyn, 
Creatine, coenzyme Q10 (CoQ10), and MitoQ have all passed 
clinical trials for the therapy of AD and HD. Since mitochon-
dria play a key role in the pathogenesis of these diseases [70], 
these clinical trials were expected to yield some positive re-
sults. However, mitochondria are involved in the pathological 
process at a relatively late stage, so the effect of these drugs 
can be expected to be limited. In fact, according to reports 
on this type of drugs, only modest therapeutic effects have 
been reported in the treatment of neurodegenerative disor-
ders [70].
Dimebon. Dimebon (Medivation Inc) showed promising re-
sults (based on cognitive tests performed on patients) in the 
second phase of AD-therapy clinical trials [71]. Dimebon also 
passed the second stage clinical trials for HD therapy and 
demonstrated a weak effect on the brain activity of patients 
(Kieburtz at al, 2010 Arch Neurology, in press)    
Dimebon is a well known antihistaminic drug used 
throughout the world and in Russia which, according to re-
ports, had a neuroprotective effect when used in picomolar 
concentrations via a new effect on the mitochondria [72]. 
However, our studies on a culture of medium spiny neurons 
from the striatum showed a reliable neuroprotective effect 
of Dimebon only at 50 μМ concentrations [73]. We concluded 
that the cognitive effect of Dimebon observed in clinical tri-
als for the treatment of AD [71] was probably caused by the 
ability of this drug to inhibit α-adrenergic, histamine, and 
serotonine high-affinity receptors [73]. In March 2010, the 
third stage clinical trials of Dimebon as a therapy for AD 
were completed and deemed to be a complete failure (http://
www.alzforum.org/new/detail.asp?id=2387). Currently, it is 
unclear whether Dimebon will be studied further as a treat-
ment for AD and HD.
Antagonists of the NMDA-receptor. Memantine is non-
competitive antagonist of the NMDA-receptor which has 
been approved by the FDA for the treatment of AD. Me-REVIEWS
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mantine is also in a clinical trial for the treatment of HD. NR 
2B-specific antagonists EVT101 and EVT103 (Evotec Inc) 
have been developed for the treatment of AD and they are 
expected to be tested in second stage clinical trials soon. The 
same drugs are also promising therapeutic compounds for the 
treatment of HD. 
Riluzole. An antiglutamate agent which has been ap-
proved by the FDA for the treatment of ALS, Riluzole has 
also competed third-stage clinical trials for the treatment of 
HD; however, it did not exhibit any reliable positive effect on 
the motor measurements performed on patients [19].
Antagonists of L-type VGCC. An “CNS-optimized” inhibi-
tor of L-type VGCC MEM-1003 (Memory Pharmaceuticals) 
showed a moderate positive effect in second stage clinical tri-
als on AD patients.  
In conclusion, we must acknowledge that research in new 
directions of brain studies using modern molecular-biological 
and electrophysiological approaches will inevitably lead to 
an elucidation of the mechanisms behind highly effective in-
formational flow and will also help discover approaches for 
treating neurodegeneration. 
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